MaxCyte share price logo

MaxCyte

NASDAQ: MXCT

$1.38

as on

MaxCyte Stock Performance

as on August 24, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $1.35
    $1.40
    downward going graph

    2.17%

    Downside

    1.45%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.64
    $1.87
    downward going graph

    53.38%

    Downside

    35.14%

    Upside

    downward going graph

MaxCyte share price movements today

Previous Close
$1.38
Open
$1.38
Volume
573.7K
Market Cap
$136.2M
Day's Low - High
$1.35 - $1.40
52 Week Low - High
$0.64 - $1.87

MaxCyte Historical Returns

1 Month Return
+ 6.45 %
3 Month Return
+ 26.92 %
1 Year Return
-2.94 %
3 Year Return
-63.84 %
5 Year Return
-91.17 %

MaxCyte Stock Fundamentals & Key Indicators

Check MaxCyte market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$136.2M

EPS (TTM)

-0.3343

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.16

Industry PE ratio

-1.4555555555555555

PEG Ratio

-0.15906858197719628

EBITDA

-32.5M

Revenue (TTM)

31.1M

Profit Margin

79.43%

Return On Equity TTM

-21.01%

MaxCyte Stock Valuation

Track how MaxCyte P/E has moved over time to understand its valuation trends.

MaxCyte in the last 5 years

  • Overview

  • Trends

Lowest (-48.39x)

December 31, 2021

Today (-3.69x)

December 31, 2025

Industry (-1.46x)

December 31, 2025

Highest (-3.69x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -3.69x

MaxCyte vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MaxCyte with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$136.2M-91.17%-4.1679.43%NA
BUY$130.1B26.77%35.2214.43%102.06%
BUY$52.8B-21.88%53.277.98%NA
BUY$116.1B-30.2%24.1565.02%3.15%
BUY$192.5B-11.49%3611.65%222.88000000000002%

Stock Returns calculator for MaxCyte Stock including INR - Dollar returns

The MaxCyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

MaxCyte investment value today

Current value as on today

₹1,10,854

Returns

₹10,854

(+10.85%)

Returns from MaxCyte Stock

₹1,471 (+1.47%)

Dollar Impact

₹9,383 (+9.38%)

Analyst Recommendation on MaxCyte Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for MaxCyte. Average target price of $4.11

MaxCyte Share Price Target

Get share price movements and forecasts by analysts on MaxCyte.

What analysts predicted

66.42%UPSIDE

Target Price

$4.11

Current Price

$1.38

Analyzed by

3 Analysts

Target

$4.11

MaxCyte target price $4.11, a slight upside of 66.42% compared to current price of $1.38. According to 3 analysts rating.

Indian Investors' Interest in MaxCyte Stock

Search interest for MaxCyte Stock has increased by 25% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:25% versus previous 30 day period

MaxCyte Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
11
10
8
8
10
8
6
7
9
7
Gross Profit
9
8
6
6
8
6
6
5
7
5
Operating Income
-12
-11
-14
-12
-12
-14
-10
-7
-6
-10
EBITDA
-8
-8
-10
-9
-8
-11
-11
-8
-3
-8
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
1
1
1
0
1
1
-
Income Before Tax
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Net Profit Margin
87.63%
85.73%
76.38%
73.76%
85.59%
82.14%
92.44%
77.95%
73.22%
76.96%

MaxCyte Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
13
16
21
26
33
44
41
38
33
Gross Profit
12
14
19
23
30
39
36
31
26
Operating Income
-9
-8
-12
-11
-18
-27
-48
-51
-45
EBITDA
-9
-7
-11
-9
-16
-20
-33
-36
-39
Interest Expense
0
0
0
0
1
0
-
-
-
Depreciation
0
0
0
1
1
2
4
4
5
Income Before Tax
-9
-8
-12
-11
-19
-23
-37
-41
-44
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-9
-8
-12
-11
-19
-23
-37
-41
-44
Net Profit Margin
89.61%
88.96%
88.44%
89.43%
89.24%
88.48%
88.51%
81.62%
81.16%

MaxCyte Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-9
-9
-11
-10
-10
-12
-12
-9
-4
-8
Operating Cash Flow
-10
-4
-4
-7
-14
-9
-7
-2
-8
-4
Investing Cash Flow
-14
19
3
-1
9
1
5
9
2
6
Financing Cash Flow
0
0
0
0
0
0
0
0
0
-1
Change in Cash
-24
15
0
-9
-4
-8
-2
7
-5
0

MaxCyte Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Mar 2021
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-9
-8
-12
-11
-19
-23
-37
-41
-44
Operating Cash Flow
-9
-10
-8
-8
-10
-14
-21
-27
-34
Investing Cash Flow
0
-3
0
-16
-195
-24
54
6
25
Financing Cash Flow
23
0
12
28
234
2
2
2
0
Change in Cash
13
-14
3
3
29
-36
35
-18
-7

Mutual Funds that own MaxCyte Stock

Check out the Mutual Funds with significant holdings in MaxCyte.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.648032%
3907833
Fidelity Salem Street Trust
1.048231%
1122883
FINANCIAL INVESTORS TRUST
0.985836%
1056045
Fidelity Concord Street Trust
0.815387%
873457
Fidelity Rutland Square Trust II
0.615511%
659346

Global Institutional Holdings in MaxCyte

Funds
Holdings
Vanguard
3.94%
Kenneth Tropin
0.01%
Counterpoint
0%

Insights on MaxCyte

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, MXCT stock has moved up by 27.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Stryker Corporation has given 19.7% return, outperforming this stock by 80.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Edwards Lifesciences Corp has given 9.7% return, outperforming this stock by 12.5%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 9.65M → 7.27M (in $), with an average decrease of 24.7% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -4.75M → -8.87M (in $), with an average decrease of 86.8% per quarter

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
OrganisationMaxCyte
Headquarters9713 Key West Avenue, Rockville, MD, United States, 20850
IndustryMedical Devices
CEOMr. Maher Masoud
E-voting on sharesClick here to vote

Key Management of MaxCyte

Name

Title

Ms. Jill Mayer

Senior Vice President of Human Resources

Mr. Maher Masoud

President, CEO & Executive Director

Mr. Parmeet Ahuja

Chief Financial Officer

Mr. Jay Gelfman

Chief Operations Officer

Mr. Jack Horgan

Senior Vice President of Corporate Development

Ms. Ana-Paula Martins Fernandes

Senior Vice President of Global Sales

FAQs

What is MaxCyte share price today?

MaxCyte share price today is $1.38 as on at the close of the market. MaxCyte share today touched a day high of $1.40 and a low of $1.35.

What is the 52 week high and 52 week low for MaxCyte share?

MaxCyte share touched a 52 week high of $1.87 on and a 52 week low of $0.64 on . MaxCyte stock price today i.e. is closed at $1.38,which is 26.01% down from its 52 week high and 114.49% up from its 52 week low.

What is MaxCyte's market capitalisation today?

MaxCyte market capitalisation is $0.00T as on .

How to invest in MaxCyte Stock (MXCT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MaxCyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MaxCyte Shares that will get you 1.0870 shares as per MaxCyte share price of $1.38 per share as on August 24, 2026 at 8:45 am IST.

What is the minimum amount required to buy MaxCyte Stock (MXCT) from India?

Indian investors can start investing in MaxCyte (MXCT) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹957.10 in MaxCyte stock (as per the Rupee-Dollar exchange rate as on ). Based on MaxCyte share’s latest price of $1.38 as on August 24, 2026 at 8:45 am IST, you will get 7.2464 shares of MaxCyte. Learn more about fractional shares .

What are the returns that MaxCyte has given to Indian investors in the last 5 years?

MaxCyte stock has given -91.17% share price returns and 29.1% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?